Drug intelligence / Profile preview

cALD SR-B

Development stage: Preclinical

Overview

cALD SR-B (Standard-Risk, Regimen B) is a named preparative regimen used in the context of hematopoietic stem cell transplantation for certain rare diseases. The term "SR-B" refers to "Standard-Risk, Regimen B," indicating it is one of several possible conditioning regimens tailored to patient risk profiles. This regimen is not a single pharmaceutical agent but rather a protocol or combination therapy used as part of transplant preparation, particularly for conditions such as cerebral adrenoleukodystrophy (cALD) and other rare disorders requiring myeloablative therapy prior to stem cell transplantation. The specific drug components and mechanisms depend on the detailed protocol but typically involve immunosuppressive and cytotoxic agents designed to ablate bone marrow and suppress immune response before transplant[1].

Brand names: cALD SR-B
Other names: CALD SR-B Standard-Risk Regimen B

Beyond the preview

Go deeper on cALD SR-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cALD SR-B.

Explore the full profile